Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
Status:
Terminated
Trial end date:
2008-05-23
Target enrollment:
Participant gender:
Summary
This is a 26-week, multicenter, randomized, double-blind, placebo and active
comparator-controlled, parallel-group study in participants with type 2 diabetes currently
sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic
monotherapy. Pioglitazone is used as active comparator. The total duration of a participant's
participation will be approximately 30 weeks, including a 2-week placebo lead-in period, a
26-week double-blind treatment period, and a 2-week post-treatment follow-up period.
Participants who complete the randomized portion of the study per protocol may have the
opportunity to continue in a long-term extension study of active treatments.